The findings indicate the survivor’s immune system held onto a memory of the virus 11 years after the infection, exemplified in the behaviors of their mAb antibodies. The primates were given antibody cocktails twice per day just one day after infection.
“Treatment with a single human mAb suggests a simplified therapeutic strategy for human Ebola infection may be possible,” the authors concluded.
More articles on infection control:
NIH evidence suggests long term health issues persist for Ebola survivors
Complications from Ebola hospitalize UK nurse again
10 interesting clinical research findings to know this week
